Insider Transactions in Q1 2024 at Cerus Corp (CERS)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 14
2024
|
Kevin Dennis Green Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
21,497
-3.36%
|
$21,497
$1.97 P/Share
|
|
Mar 14
2024
|
Chrystal Menard Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
17,824
-3.5%
|
$17,824
$1.97 P/Share
|
|
Mar 14
2024
|
William Mariner Greenman President and CEO |
SELL
Open market or private sale
|
Direct |
63,611
-1.96%
|
$127,222
$2.02 P/Share
|
|
Mar 14
2024
|
Vivek K Jayaraman Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
26,794
-2.96%
|
$26,794
$1.97 P/Share
|
|
Mar 14
2024
|
Laurence M Corash Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
14,360
-0.61%
|
$14,360
$1.97 P/Share
|
|
Mar 14
2024
|
Richard J Benjamin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
17,738
-3.72%
|
$17,738
$1.97 P/Share
|
|
Mar 13
2024
|
Kevin Dennis Green Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
21,058
-3.18%
|
$42,116
$2.02 P/Share
|
|
Mar 13
2024
|
Chrystal Menard Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
17,460
-3.32%
|
$34,920
$2.06 P/Share
|
|
Mar 13
2024
|
Carol Moore SVP Reg. & Quality |
SELL
Open market or private sale
|
Direct |
20,619
-2.04%
|
$41,238
$2.02 P/Share
|
|
Mar 13
2024
|
William Mariner Greenman President and CEO |
SELL
Open market or private sale
|
Direct |
62,315
-1.88%
|
$124,630
$2.06 P/Share
|
|
Mar 13
2024
|
Vivek K Jayaraman Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
26,247
-2.82%
|
$52,494
$2.06 P/Share
|
|
Mar 13
2024
|
Laurence M Corash Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
14,067
-0.59%
|
$28,134
$2.06 P/Share
|
|
Mar 13
2024
|
Richard J Benjamin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
17,377
-3.51%
|
$34,754
$2.06 P/Share
|
|
Mar 12
2024
|
Kevin Dennis Green Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,666
+3.17%
|
-
|
|
Mar 12
2024
|
Chrystal Menard Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,666
+3.07%
|
-
|
|
Mar 12
2024
|
Carol Moore SVP Reg. & Quality |
BUY
Exercise of conversion of derivative security
|
Direct |
11,666
+2.23%
|
-
|
|
Mar 12
2024
|
William Mariner Greenman President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
64,666
+1.92%
|
-
|
|
Mar 12
2024
|
Vivek K Jayaraman Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+2.61%
|
-
|
|
Mar 12
2024
|
Laurence M Corash Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,666
+0.7%
|
-
|
|
Mar 12
2024
|
Richard J Benjamin Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,666
+3.26%
|
-
|
|
Mar 08
2024
|
Richard J Benjamin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
29,378
-5.79%
|
$58,756
$2.4 P/Share
|
|
Mar 01
2024
|
Vivek K Jayaraman Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
240,000
+20.93%
|
-
|
|
Mar 01
2024
|
Chrystal Menard Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
160,000
+23.9%
|
-
|
|
Mar 01
2024
|
Carol Moore SVP Reg. & Quality |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+13.05%
|
-
|
|
Mar 01
2024
|
Laurence M Corash Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+3.69%
|
-
|
|
Mar 01
2024
|
Kevin Dennis Green Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+23.82%
|
-
|
|
Mar 01
2024
|
William Mariner Greenman President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
575,000
+15.06%
|
-
|
|
Mar 01
2024
|
Richard J Benjamin Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
160,000
+23.97%
|
-
|